BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 28659337)

  • 1. Anaplastic lymphoma kinase-positive anaplastic large cell lymphoma with the variant RNF213-, ATIC- and TPM3-ALK fusions is characterized by copy number gain of the rearranged ALK gene.
    van der Krogt JA; Bempt MV; Ferreiro JF; Mentens N; Jacobs K; Pluys U; Doms K; Geerdens E; Uyttebroeck A; Pierre P; Michaux L; Devos T; Vandenberghe P; Tousseyn T; Cools J; Wlodarska I
    Haematologica; 2017 Sep; 102(9):1605-1616. PubMed ID: 28659337
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular Screening in Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma: Anaplastic Lymphoma Kinase Analysis, Next-Generation Sequencing Fusion Gene Detection, and T-Cell Receptor Immunoprofiling.
    Kalinova M; Mrhalova M; Kabickova E; Svaton M; Skotnicova A; Prouzova Z; Krenova Z; Kolenova A; Divoka M; Fronkova E; Kodet R
    Mod Pathol; 2024 Mar; 37(3):100428. PubMed ID: 38266918
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The NPM-ALK and the ATIC-ALK fusion genes can be detected in non-neoplastic cells.
    Maes B; Vanhentenrijk V; Wlodarska I; Cools J; Peeters B; Marynen P; de Wolf-Peeters C
    Am J Pathol; 2001 Jun; 158(6):2185-93. PubMed ID: 11395396
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Variant ALK-fusion positive anaplastic large cell lymphoma (ALCL): A population-based paediatric study of the NHL-BFM study group.
    Luedersen J; Stadt UZ; Richter J; Oschlies I; Klapper W; Rosenwald A; Kalinova M; Simonitsch-Klupp I; Siebert R; Zimmermann M; Qi M; Nakel J; Scheinemann K; Knörr F; Attarbaschi A; Kabickova E; Woessmann W; Damm-Welk C
    Br J Haematol; 2024 Jan; ():. PubMed ID: 38279625
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progress in the identification of subgroups in ALK-negative anaplastic large-cell lymphoma.
    Boddicker RL; Feldman AL
    Biomark Med; 2015; 9(8):719-22. PubMed ID: 26223379
    [No Abstract]   [Full Text] [Related]  

  • 6. ALK-negative anaplastic large cell lymphoma with JAK2 rearrangement mimicking classic Hodgkin lymphoma.
    Jaye DL; Feldman AL
    Blood; 2023 Apr; 141(17):2160. PubMed ID: 37103947
    [No Abstract]   [Full Text] [Related]  

  • 7. Determining the contribution of NPM1 heterozygosity to NPM-ALK-induced lymphomagenesis.
    Mduff FK; Hook CE; Tooze RM; Huntly BJ; Pandolfi PP; Turner SD
    Lab Invest; 2011 Sep; 91(9):1298-303. PubMed ID: 21709672
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of TRAF1-ALK fusion in skin lesions of systemic ALK+ anaplastic large cell lymphoma initially involving the skin and the draining lymph node.
    Norimatsu Y; Akatsuka T; Matsuoka A; Hamada T; Mori I; Shiomi T; Mori N; Onishi K; Togashi Y; Inoue N; Takeuchi K; Sugaya M
    J Dermatol; 2024 Jan; 51(1):120-124. PubMed ID: 37753577
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of high-risk DUSP22-rearranged ALK-negative anaplastic large cell lymphoma.
    Hapgood G; Ben-Neriah S; Mottok A; Lee DG; Robert K; Villa D; Sehn LH; Connors JM; Gascoyne RD; Feldman AL; Farinha P; Steidl C; Scott DW; Slack GW; Savage KJ
    Br J Haematol; 2019 Aug; 186(3):e28-e31. PubMed ID: 30873584
    [No Abstract]   [Full Text] [Related]  

  • 10. Chimeric kinase ALK induces expression of NAMPT and selectively depends on this metabolic enzyme to sustain its own oncogenic function.
    Zhang Q; Basappa J; Wang HY; Nunez-Cruz S; Lobello C; Wang S; Liu X; Chekol S; Guo L; Ziober A; Nejati R; Shestov A; Feldman M; Glickson JD; Turner SD; Blair IA; Van Dang C; Wasik MA
    Leukemia; 2023 Dec; 37(12):2436-2447. PubMed ID: 37773266
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characteristics of Renal Cell Carcinoma Harboring
    Woo CG; Yun SJ; Son SM; Lim YH; Lee OJ
    Yonsei Med J; 2020 Mar; 61(3):262-266. PubMed ID: 32102128
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anaplastic large cell lymphoma with ALK::ATIC fusion mimicking a histiocytic sarcoma debuting as an anterior thoracic soft tissue tumor with exceptional clinicopathological, morphological and molecular features.
    García-Muñiz JA; Vilches-Cisneros N; Flores-Gutiérrez JP; Barboza-Quintana O
    Thorac Cancer; 2024 May; 15(13):1103-1105. PubMed ID: 38523398
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ALK-TPM3 rearrangement in adult renal cell carcinoma: a case report and literature review.
    Yang J; Dong L; Du H; Li XB; Liang YX; Liu GR
    Diagn Pathol; 2019 Oct; 14(1):112. PubMed ID: 31627758
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Savage KJ; Slack GW
    Haematologica; 2023 Jun; 108(6):1463-1467. PubMed ID: 36453106
    [No Abstract]   [Full Text] [Related]  

  • 15. [Cutaneous ALK rearranged spindle cell neoplasm and S-100/CD34 co-expression: report of a case].
    Zhang W; Wang Y; Wang H; Gao Y; Chen YL
    Zhonghua Bing Li Xue Za Zhi; 2024 May; 53(5):498-500. PubMed ID: 38678336
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ALK-positive histiocytosis: a new clinicopathologic spectrum highlighting neurologic involvement and responses to ALK inhibition.
    Kemps PG; Picarsic J; Durham BH; Hélias-Rodzewicz Z; Hiemcke-Jiwa L; van den Bos C; van de Wetering MD; van Noesel CJM; van Laar JAM; Verdijk RM; Flucke UE; Hogendoorn PCW; Woei-A-Jin FJSH; Sciot R; Beilken A; Feuerhake F; Ebinger M; Möhle R; Fend F; Bornemann A; Wiegering V; Ernestus K; Méry T; Gryniewicz-Kwiatkowska O; Dembowska-Baginska B; Evseev DA; Potapenko V; Baykov VV; Gaspari S; Rossi S; Gessi M; Tamburrini G; Héritier S; Donadieu J; Bonneau-Lagacherie J; Lamaison C; Farnault L; Fraitag S; Jullié ML; Haroche J; Collin M; Allotey J; Madni M; Turner K; Picton S; Barbaro PM; Poulin A; Tam IS; El Demellawy D; Empringham B; Whitlock JA; Raghunathan A; Swanson AA; Suchi M; Brandt JM; Yaseen NR; Weinstein JL; Eldem I; Sisk BA; Sridhar V; Atkinson M; Massoth LR; Hornick JL; Alexandrescu S; Yeo KK; Petrova-Drus K; Peeke SZ; Muñoz-Arcos LS; Leino DG; Grier DD; Lorsbach R; Roy S; Kumar AR; Garg S; Tiwari N; Schafernak KT; Henry MM; van Halteren AGS; Abla O; Diamond EL; Emile JF
    Blood; 2022 Jan; 139(2):256-280. PubMed ID: 34727172
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ALK-rearranged CD30-positive poorly differentiated lung adenocarcinoma, mimicking anaplastic large-cell lymphoma.
    George GV; Wallace DS; Wang Y; Carney J; Elsadawi M; Burack WR; Evans AG; Barr PM; Velez MJ; El Hussein S
    Histopathology; 2024 Apr; 84(5):900-902. PubMed ID: 38032068
    [No Abstract]   [Full Text] [Related]  

  • 18. A cutaneous epithelioid vascular tumor harboring a TPM3::ALK fusion.
    Linos K; Chang JC; Busam KJ
    Genes Chromosomes Cancer; 2024 Jan; 63(1):e23207. PubMed ID: 37787425
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination therapy with crizotinib and vinblastine for relapsed or refractory pediatric ALK-positive anaplastic large cell lymphoma.
    Knörr F; Schellekens KPJ; Schoot RA; Landman-Parker J; Teltschik HM; Förster J; Riquelme A; Huitema ADR; Van Eijkelenburg NKA; Beishuizen A; Zwaan CM; Woessmann W; Van der Lugt J
    Haematologica; 2023 May; 108(5):1442-1446. PubMed ID: 36519329
    [No Abstract]   [Full Text] [Related]  

  • 20. Teaching NeuroImage: Branching Dura Mater in Primary CNS ALK-Positive Anaplastic Large Cell Lymphoma.
    Rattanawong W; Tekarnjnavanit A; Marukatat C; Hemachudha P; Pongpitakmetha T; Anukoolwittaya P
    Neurology; 2023 Oct; 101(17):766-768. PubMed ID: 37536956
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.